TY  - JOUR

T1  - Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in metastatic hormone sensitive prostate cancer (mHSPC).

JO  - Journal of Clinical Oncology

UR  - https://doi.org/10.1200/jco.2025.43.5_suppl.184

PY  - 2025/02/10

AU  - Naqvi SAA

AU  - Faisal KS

AU  - Khakwani KZR

AU  - Childs DS

AU  - Orme J

AU  - Andrews J

AU  - Ravi P

AU  - Hussain SA

AU  - Agarwal N

AU  - Singh P

AU  - Zakharia Y et al

ED  - 

DO  - DOI: 10.1200/jco.2025.43.5_suppl.184

PB  - American Society of Clinical Oncology (ASCO)

VL  - 43

IS  - 5_suppl

SP  - 184

EP  - 184

Y2  - 2025/03/10

ER  -